Intercept Pharmaceuticals Overview and History

Intercept Pharmaceuticals has a unique story that began with its founding in 2007.

The company was founded by Mark Pruzanski and Howard Mayer, two experienced pharmaceutical executives who shared a vision of developing innovative treatments for liver diseases.

Their first product, obeticholic acid (OCA), was initially developed to treat primary biliary cholangitis (PBC), a rare autoimmune disease that affects the liver.

OCA was designed to mimic a natural bile acid, which the body produces to help digest fat.

Intercept Pharmaceuticals has a long history of innovation in the pharmaceutical industry, dating back to its founding in 1995 by Howard W. Robin and Mark Pruzanski. The company's early focus was on developing treatments for rare and chronic diseases.

The company's first product, Actigall, was approved by the FDA in 1988, but Intercept Pharmaceuticals acquired the rights to the medication in 2002. Actigall is a bile acid sequestrant used to treat primary biliary cirrhosis.

In 2012, Intercept Pharmaceuticals launched its own research and development program, which led to the development of obeticholic acid, a medication that would eventually become the company's flagship product.

Intercept Pharmaceuticals made its initial public offering on October 16, 2012, at $15 per share.

The stock was traded on the NASDAQ exchange under the ticker symbol ICPT.

A follow-on public offering took place on June 24, 2013, at $33 per share.

On January 9, 2014, the stock price skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis showed that Obeticholic acid met the main goal in the FLINT trial.

Here's a brief timeline of the stock's performance in 2014:

The company continued to release positive results, including the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint in March 2014.

The stock's market capitalization reached around $6.2 billion on March 29, 2014.

Nash, a leading manufacturer of automotive parts, had its hopes of independence dashed in 1988 when it was acquired by the American Motors Corporation for $794 million.

The buyout was a significant blow to Nash's employees, who had been hoping for a more stable future under private ownership.

The acquisition was a major milestone in the history of Nash, marking the end of its independence and the beginning of a new era under corporate ownership.

Nash's employees were left to wonder what the future held for their company, and whether they would be able to maintain their jobs and benefits under new management.

The buyout also had significant implications for the automotive industry as a whole, as it marked a major shift in the balance of power among manufacturers.

The $794 million price tag was a staggering sum at the time, and it set a new standard for buyouts in the industry.

Nash's acquisition by American Motors Corporation had a lasting impact on the company and its employees, and it remains an important chapter in the history of the automotive industry.

A different take: Logistics in Pharmaceutical Industry

Intercept Pharmaceuticals Inc has seen a significant increase in sales over the years, with a notable boost in revenue from their drug sales.

According to the sales and consensus forecasts, the company is expected to continue growing, with an 8-year patient population forecast that will provide a substantial market opportunity for new entrants.

The drug revenue for Intercept Pharmaceuticals Inc is projected to increase steadily, providing a stable financial foundation for the company.

The sales forecasts indicate that the company's revenue will reach new heights, making it an attractive investment opportunity for those looking to get in on the ground floor.

As the market continues to grow, it's essential to stay up-to-date on the latest sales and consensus forecasts to make informed investment decisions.

Curious to learn more? Check out: New World First Bus

The Latest SEC Filings are a great way to stay up-to-date on a company's financial activity. There were multiple filings made on November 8, 2023, indicating a busy day for the company.

Intriguing read: Johnson & Johnson - Merck Consumer Pharmaceuticals Company

The filings included a Current Report, which is a report that companies must file with the SEC when there's significant news or events that affect their business. This report was filed under the 8-K form.

One of the most interesting filings was the Post-Effective amendments for registration statement, which was filed under the POS AM form. This type of filing is used when a company wants to make changes to a registration statement that has already been filed with the SEC.

Here are the details of the filings made on November 8, 2023:

The company also filed multiple S-8 POS forms, which is used when a company wants to offer securities to its employees. These filings are often used to offer stock options or other equity compensation to employees.

With access to company-related investigative journalist content, Intercept Pharmaceuticals can remove risk and uncertainty, gain a competitive edge, and secure actionable leads.

This content can provide valuable insights into the company's operations, helping Intercept Pharmaceuticals make informed decisions and stay ahead of the competition.

By leveraging this investigative journalist content, Intercept Pharmaceuticals can uncover new information and identify potential opportunities or threats, ultimately driving business success.

Intercept Pharmaceuticals Inc has a clear focus on commercializing its premium products, allowing businesses to stay ahead of the market. Their product portfolio is a key factor in this strategy.

Ocaliva (Obeticholic Acid) is a marketed product used to treat Primary Biliary Cholangitis (PBC).

Their pipeline candidates are also worth noting, with multiple XYZ products in development.

Let's dive into the world of competitor comparison. We've got a list of five major players in the industry: Intercept Pharmaceuticals Inc, AstraZeneca Plc, Novartis AG, Bristol-Myers Squibb Co, and Novo Nordisk AS.

AstraZeneca Plc is a public entity with a massive workforce of 94,300 employees.

Novartis AG is also a public entity with a significant presence in Switzerland, boasting 75,883 employees.

Bristol-Myers Squibb Co is a public entity based in the United States, employing 34,100 people.

Novo Nordisk AS is a public entity from Denmark, with a substantial workforce of 68,669 employees.

Intercept Pharmaceuticals Inc is a private entity based in the United States, with its headquarters in Morristown, New Jersey.

The table below summarizes the key parameters of these competitors:

Intercept Pharmaceuticals is dedicated to conducting thorough clinical trials to ensure the safety and efficacy of their products.

The company's clinical operations involve a strategic approach to recruitment, aiming to find the right participants for their trials.

Their clinical trial strategy is designed to provide valuable insights into the effectiveness of their treatments.

Intercept Pharmaceuticals' focus on clinical trials is a testament to their commitment to delivering high-quality products.

By conducting rigorous clinical trials, the company is able to gather reliable data that informs their go-to-market proposition.

This approach allows them to make informed decisions about their products and ultimately bring them to market with confidence.

Intercept Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing treatments for non-viral liver diseases.

The company was founded in 2002 and is headquartered in New York City.

Its lead product, Ocaliva (obeticholic acid), was approved by the FDA in 2016 for the treatment of primary biliary cholangitis (PBC).

Intercept Pharmaceuticals Inc has a lead product called Ocaliva, also known as obeticholic acid or OCA, which is a potent first-in-class farnesoid X receptor (FXR) agonist.

OCA is used to treat primary biliary cholangitis, a rare autoimmune liver disease. The U.S. Food and Drug Administration (FDA) approved Ocaliva for this use in 2016.

The European Medicines Agency (EMA) recommended revoking Ocaliva's marketing authorization in June 2024, citing that the benefits no longer outweigh the risks. The European Commission officially revoked the authorization on August 30, 2024.

In the U.S., Ocaliva remains available under accelerated approval, which requires ongoing post-marketing studies to confirm its clinical benefits. The FDA is continuing to review data from these studies.

Other products in development include INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist.

A different take: Central European Media Enterprises

The key executives at this company are a talented group of individuals who drive the organization's success. Jerome B. Durso serves as the President, Chief Executive Officer, and Director.

Jerome B. Durso is the President, Chief Executive Officer, and Director of the company. He's a seasoned leader with a wealth of experience in the industry.

Andrew Saik is the Chief Financial Officer, responsible for managing the company's finances and making strategic financial decisions. His expertise has been instrumental in the company's growth.

Rocco Venezia is the Chief Accounting Officer and Treasurer, overseeing the company's financial reporting and compliance. His attention to detail ensures the company's financials are always in order.

Jared M. Freedberg J.D. serves as the General Counsel, providing legal guidance and support to the company. His expertise has been invaluable in navigating complex legal matters.

Dr. M. Michelle Berrey M.D., M.P.H., MPH. is the President of Research & Development and Chief Medical Officer, leading the company's research efforts and medical initiatives. Her medical expertise has been instrumental in developing new treatments.

Nareg Sagherian is the Executive Director of Global Investor Relations, responsible for managing the company's relationships with investors and the financial community. His experience has helped build strong relationships with key stakeholders.

Expand your knowledge: Silicon Valley Bank Chief Investment Officer

David Ford is the Chief Human Resources Officer, overseeing the company's human resources function and ensuring the well-being of its employees. His leadership has created a positive and supportive work environment.

Here is a list of the key executives: